. Author manuscript; available in PMC: 2014 Jan 9.

Published in final edited form as: Gynecol Oncol. 2012 Aug 10;127(2):10.1016/j.ygyno.2012.08.001. doi: 10.1016/j.ygyno.2012.08.001

Table 1.

Patient Characteristics.

	Bevacizumab (n=17)	No Bevacizumab (n=19)	P-value

Age (median)	58	58
Race			p = .1427
White	17 (100%)	18 (94.74%)
AA		1 (5.26%)

Primary Debulking			p = .7624
Surgery
Optimal	15 (88.24%)	16 (84.21%)
Suboptimal	2 (11.76%)	3 (15.79%)

Stage			p = .2157
I/II	1 (5.88%)	0
III/IV	16 (94.12%)	19 (100%)

Histology			p = .4787
Serous	15 (88.24%)	18 (94.74%)
Other	2 (11.76%)	1 (5.26%)

Primary Platinum Sensitive			p = .3403
Yes	11 (64.71%)	15 (78.95%)
No	6 (35.29%)	5 (21.05%)

Bev first line			p = .0637
Yes	1 (5.88%)	4 (21.05%)
No	16 (94.12%)	15 (78.95)

Median # regimens before bev (range)	2.5 (0–6)	1 (0–4)	p = .09
Median # months between first bev regimen and subsequent regimen (range)	7.53 (.4–32.2)	7.13 (.2–21.6)	p = .8784

Median Ca125 prior to treatment with bev	94	90.5